SCHEMBL1900118

SCHEMBL1900118

Cc1[c]nn(-c2ccccc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.42
NOTUM Q6P988 2/20 0.41
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PARP1 P09874 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
GLA P06280 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MGLL Q99685 1/20 0.35
ADRB1 P08588 1/20 0.34
HSD11B1 P28845 1/20 0.34
HCAR1 Q9BXC0 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698835 0.81 NOTUM (0.45) NOTUMALDH1A1MAPTNPSR1HSD11B1
SCHEMBL1898960 0.79 ADORA1 (0.42) NOTUMADORA3MGLLKCNN4
SCHEMBL1903300 0.76 MGLL (0.41) ALDH1A1KDM4EMAPTSMN1; SMN2ADORA3
SCHEMBL9131851 0.69 TDO2 (0.46) BCHENOTUMALDH1A1KDM4EMAPT
SCHEMBL14996591 0.69 CYP1A2 (0.44) BCHENOTUMALDH1A1KDM4EMAPT
SCHEMBL6271350 0.68 BCHE (0.46) BCHENOTUMSMN1; SMN2PARP1ADORA3
SCHEMBL717248 0.67 PARP1 (0.41) BCHENOTUMALDH1A1KDM4EMAPT
SCHEMBL2615993 0.67 MAPT (0.52) BCHENOTUMALDH1A1KDM4EMAPT
SCHEMBL979801 0.67 BCHE (0.41) BCHENOTUMALDH1A1PARP1ADORA3
SCHEMBL19313252 0.67 PARP1 (0.43) BCHENOTUMALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 BCHE 3623/4885NOTUM 1571/4885ALDH1A1 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.